A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)
European Journal of Cancer2011Vol. 47(15), pp. 2331–2340
Citations Over TimeTop 1% of 2011 papers
Rabab Gaafar, Veerle Surmont, Giorgio V. Scagliotti, Rob J. van Klaveren, Demetris Papamichael, John J. Welch, Baktiar Hasan, Valter Torri, Jan P. van Meerbeeck
Related Papers
- → Creation of Patient Education System for Use of Gefitinib in Treatment of Non-small Cell Lung Cancer(2007)1 cited
- → P3-161: Gefitinib toxicity has been significantly correlated with survival in non-small cell lung cancer patients treated in EAP program in Czech Republic(2007)
- → Sequential Therapy with Gefitinib for Advanced Non-Small Cell Lung Cancer(2008)
- Gefitinib and Eelotinib in treatment of advanced non-small cell lung cancer(2010)
- CLINICAL EFFECT OF GEFITINIB ON ADVANCED NON-SMALL CELL LUNG CANCER(2012)